What Happened

The FDA extended its review of Exelixis' zanzalintinib in combination with Roche's Tecentriq for metastatic colorectal cancer (mCRC). The agency requested updated safety and efficacy data, pushing the decision from Dec. 3, 2026 to March 2027.

The application had already been under pressure after zanzalintinib missed one of two primary overall survival endpoints in a subpopulation of a Phase 3 study in June. Analysts at William Blair still see low rejection risk, citing the overall promising Phase 3 data.

Who Is Affected

Exelixis is the primary company affected, with its regulatory timeline for a key oncology asset now extended. Roche, as the partner supplying Tecentriq, also has a direct stake in the outcome.

The delay also affects the competitive landscape in mCRC, where Exelixis' combo would compete with Bayer's Stivarga, Amgen's Lumakras, and Takeda's Fruzaqla.

Market Impact

The extended review creates near-term commercial-planning and data-management needs at Exelixis, as the company must prepare updated safety and efficacy submissions.

• Additional data requirements may drive increased clinical-data and regulatory-software spend.
• Competitive pressure in mCRC intensifies while reference therapies remain on the market.
• Analyst estimates suggest zanzalintinib could reach $4.5 billion in U.S. sales across indications, making the regulatory outcome material.

What to Watch

Watch for the Stellar-304 readout in non-clear cell renal cell carcinoma, expected in the second half of this year, which could influence Exelixis' broader zanzalintinib franchise.

Also monitor whether the FDA's data request signals a more cautious stance on the combo. The March 2027 PDUFA date is the next major catalyst for the asset.

Related coverage

• Roche pays $190M upfront for obesity drug rights
• FDA approves eGenesis pig liver trial for acute liver failure treatment
• FDA approves Revolution Medicines' daraxonrasib for advanced pancreatic cancer
• FDA Accepts NDA for Apnimed's Sleep Apnea Pill AD109